Amorfix research and development programs leading the way for new therapeutics for ALS

Amorfix research and development programs leading the way for new therapeutics 
for ALS 
TORONTO, Nov. 7, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that 
anti-SOD1 antibodies developed by the company are being used by a leading 
academic scientist, Dr. Serge Przedborski at Columbia University, to 
investigate the pathogenesis and mechanisms of disease progression in 
ALS.This research is in addition to and complements the ongoing development 
of antibodies against misfolded SOD1 through a licensing agreement with 
Biogen-Idec. 
"This collaboration is designed to help answer key questions about the pivotal 
role of misfolded SOD1 in ALS" said Amorfix Chief Scientific Officer and 
Company founder Dr. Neil Cashman. "Understanding the disease from a 
mechanistic perspective will greatly facilitate the development of new 
treatments that can effectively treat ALS patients and hopefully prevent 
further decline in neurological function". 
Dr. Przedborski will be utilizing anti-SOD1 antibodies developed by Amorfix to 
investigate toxic effects of misfolded SOD1 on motor neurons, the cells that 
degenerate in ALS. The project seeks to understand which cells in the nervous 
system generate toxic misfolded SOD1, and ultimately to use the anti-SOD1 
antibodies to block this toxicity to protect motor neurons. 
"There is increasing recognition that non-neuronal cells contribute to the 
death of neuronal cells in a disease such as ALS, yet, how non-neuronal cells 
actually kill neuronal cells remains enigmatic," said Dr. Przedborski. "I 
believe that with the anti-SOD1 antibodies developed by Amorfix, we are now in 
a position to address one of the key outstanding questions about the biology 
of ALS which is whether or not misfolded SOD1 is instrumental in the 
deleterious process." 
The proprietary antibodies were developed by Amorfix and validated by the 
ProMIS discovery platform, and have been licensed to Biogen-Idec for the 
development of antibody therapeutics, and to Pan Provincial Vaccine Enterprise 
(PREVENT) for the development of vaccine applications. Both of these programs 
are advancing in preclinical development. In addition, the Company is 
developing a blood test to be used as a diagnostic tool for the early 
detection of ALS, based on the detection of misfolded SOD1 in plasma. 
About Amorfix
Amorfix Life Sciences Ltd. (TSX: AMF) is an early-stage product development 
company developing therapeutic antibodies and diagnostics targeting misfolded 
protein diseases. Amorfix utilizes its computational discovery platform, 
ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular 
surface of misfolded proteins. Using this technology, Amorfix is developing 
novel antibody therapeutics and companion diagnostics for cancer and 
amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two 
proprietary technologies to specifically identify very low levels of misfolded 
proteins in a biological sample: Epitope Protection™ and AMFIA™, an 
ultra-sensitive dual-bead immunoassay. Use of these technologies has generated 
a cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD) and 
mild cognitive impairment (MCI), and an ultrasensitive method for detecting 
the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood 
from animal models of AD. For more information about Amorfix, visit 
www.amorfix.com. 
The TSX has not reviewed and does not accept responsibility for the adequacy 
or accuracy of this release. 
This news release contains certain forward-looking information, which involves 
known and unknown risks, uncertainties and other factors that may cause actual 
results, performance or achievements to be materially different from those 
implied by statements herein, and therefore these statements should not be 
read as guarantees of future performance or results. All forward-looking 
statements are based on the Company's current beliefs as well as assumptions 
made by and information currently available to it, such as the commitments of 
potential subscribers that are not binding legal obligations, as well as other 
factors, that are subject to change. Readers are cautioned not to place 
undue reliance on these forward-looking statements, which speak only as of the 
date of this press release. Due to risks and uncertainties, including the 
risks and uncertainties identified by the Company in its public securities 
filings, actual events may differ materially from current expectations. The 
Company disclaims any intention or obligation to update or revise any 
forward-looking statements, whether as a result of new information, future 
events or otherwise, unless required by law. 
ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life 
Sciences Ltd. 
Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences 
Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com 
Janet Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 
847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com 
SOURCE: Amorfix Life Sciences Ltd. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2012/07/c5660.html 
CO: Amorfix Life Sciences Ltd.
ST: Ontario
NI: MTC NP  
-0- Nov/07/2012 12:20 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.